Effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy on serum levels of HE4 and DJ-1 in patients with advanced recurrent ovarian cancer.

Yanhui Kang,Xianhui Su,Yuna Dai,Xuewen Sun

doi:10.12669/pjms.38.4.4736

Abstract

Objective:To analyze the effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy (IPCH) on serum levels of human epididymis protein 4 (HE4) and mitogen-dependent oncogene-1 (DJ-1) in patients with advanced recurrent ovarian cancer (OC).Methods:From July 2019 to July 2020, patients with advanced recurrent OC (n=92) treated in Affiliated Hospital of Hebei Engineering University were selected as study subjects. According to the random number table method, patients were divided into control group and observation group. Patients in the control group were treated with carboplatin combined with paclitaxel-based intravenous chemotherapy, and patients in the observation group were treated with carboplatin combined with paclitaxel-based IPCH. The therapeutic effects, serum levels of HE4, DJ-1 and human kallikrein 10 (HK-10), peripheral blood immune indexes and adverse reactions of patients were compared between the two groups.Results:The response rate of the observation group was significantly higher than that of the control group (p<0.05); after treatment, the indexes of HE4, DJ-1 and HK-10 in the two groups were significantly decreased, while the indexes of CD3+CD4+, CD3+CD56+ and CD3+CD4+/CD3+CD8+ were significantly increased; moreover, significantly lower indexes of HE4, DJ-1 and HK-10 and significantly higher indexes of CD3+CD4+, CD3+CD56+ and CD3+CD4+/CD3+CD8+ were found in the observation group when compared with the control group (p<0.05). The severity of myelosuppression, nausea and vomiting in the observation group was significantly lower than that in the control group, and the total tumor metastasis rate in the observation group was significantly lower than that in the control group (p<0.05).Conclusions:Carboplatin combined with paclitaxel IPCH had obvious inhibitory effects on HE4, DJ-1 and other serum tumor markers in patients with advanced recurrent OC, with a more prominent clinical effect, and could further significantly reduce the risk of adverse reactions and metastasis.

Highlights

Ovarian cancer (OC), a malignant tumor growing in ovarian tissues, was more common in gynecologic malignancies
The results of our study showed that the response rate of the observation group was significantly higher than that of the control group, while the total tumor metastasis rate of the observation group was significantly lower than that of the control group, indicating that carboplatin combined with paclitaxel intraperitoneal hyperthermic perfusion chemotherapy (IPCH) was more helpful to control the disease progression of advanced recurrent epithelial OC and reduce the risk of metastasis; and a previous study of Kuittinen et al.[17] supported our results
Comparative analysis on the serum tumor markers of patients were carried out, and the results showed that, after treatment, the indexes of human epididymis protein 4 (HE4), dependent oncogene-1 (DJ-1) and human kallikrein 10 (HK-10) in the two groups decreased significantly, suggesting that the two chemotherapy methods may be helpful in the treatment of patients with advanced recurrent epithelial OC

Summary

INTRODUCTION

Ovarian cancer (OC), a malignant tumor growing in ovarian tissues, was more common in gynecologic malignancies. Patients in the control group were 30-60 years old, with an average age of 44.59 ± 1.33 years old; as for tumor typing, there were 27 cases of serous adenocarcinoma, 10 cases of endometrioid carcinoma and nine cases of mucinous adenocarcinoma; regarding clinical staging, there were 18 cases of stage IIIa, 16 cases of stage IIIb, 12 cases of stage IV. Patients in the observation group was 32-64 years old, with an average age of 45.06 ± 5.28 years old; as for tumor typing, there were 26 cases of serous adenocarcinoma, 11 cases of endometrioid carcinoma and 9 cases of mucinous adenocarcinoma; regarding clinical staging, there were cases of stage IIIa, cases of stage IIIb and 13 cases of stage IV.

RESULTS

DISCUSSION

CONCLUSION